Hegab Mohammed H A, Hassan Rashed M
Department of Parasitology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Egypt Soc Parasitol. 2003 Aug;33(2):561-70.
Sixty-eight individuals were included in this study, 30 of them presented with Fasciola infection, 20 were infected with other parasites but not Fasciola (infected control group) and 18 individuals were parasite-free (normal control group). For all groups, stool analysis by modified formol-ether technique and Kato thick smears for egg counts and the circulating Fasciola antigens (CFAgs) and anti- Fasciola IgG4 isotype were estimated by ELISA technique. Complete blood count, liver functions tests and abdominal ultra-sonography were performed for all Fasciola-infected patients. Patients with fascioliasis received a myrrh-derived drug (Mirazid) in a dose of 10 mg/kg b.wt., one hour before breakfast for six consecutive days. Remeasuring of the above parameters was performed one and three months after therapy. Detection of CFAgs was found to be a useful marker for assessment of core. No cross reaction was observed between Fasciola and other parasites by using CFAg (100% specificity). The level of these antigens correlated positively with signs of cure; parasitologically, clinically or ultrasonographically. Detection of IgG4 isotype was found to be a more sensitive and accurate immunodignostic tool for fascioliasis, but it was not a useful marker for assessment of cure. Mirazid drug possesses high therapeutic efficacy (100% cure rate) on fascioliasis without remarkable side effects.
本研究纳入了68名个体，其中30人感染了片形吸虫，20人感染了其他寄生虫但未感染片形吸虫（感染对照组），18人未感染寄生虫（正常对照组）。对所有组均采用改良甲醛乙醚技术进行粪便分析，并通过加藤厚涂片法进行虫卵计数，采用酶联免疫吸附测定（ELISA）技术检测循环中的片形吸虫抗原（CFAgs）和抗片形吸虫IgG4同种型。对所有感染片形吸虫的患者进行了全血细胞计数、肝功能检查和腹部超声检查。患有片形吸虫病的患者在早餐前1小时服用一种没药衍生药物（米拉齐德），剂量为10 mg/kg体重，连续服用6天。在治疗后1个月和3个月对上述参数进行重新测量。发现检测CFAgs是评估疗效的一个有用指标。使用CFAg检测时，片形吸虫与其他寄生虫之间未观察到交叉反应（特异性为100%）。这些抗原的水平与治愈迹象呈正相关；无论是在寄生虫学、临床还是超声检查方面。发现检测IgG4同种型是诊断片形吸虫病更敏感和准确的免疫诊断工具，但它不是评估治愈情况的有用指标。米拉齐德药物对片形吸虫病具有高治疗效果（治愈率100%），且无明显副作用。
